" class="no-js "lang="en-US"> Arthur Roach - Medtech Alert
Thursday, September 04, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Arthur Roach

Arthur Roach

About Arthur Roach

 

  • Director of Research at Parkinson’s UK since 2014
  • 22 years pharma and biotech experience in CNS diseases area
  • Senior Director in Neurodegeneration Research at Merck Serono (2002-2012)

Related Story

Central Nervous System

 NRG Therapeutics Announces £2.68m Innovate UK Award to Develop New Medicines to Treat Parkinson's and Motor Neuron Disease | Pharmtech Focus

NRG Therapeutics Announces £2.68m Innovate UK Award to Develop New Medicines to Treat Parkinson's and Motor Neuron Disease

May 30 2022

NRG Therapeutics Ltd (“NRG” or “company”), an innovative neuroscience company targeting mitochondrial dysfunction, is pleased […]